Skip to search formSkip to main contentSkip to account menu

gefitinib

Known as: 4-(3Chloro-4-flurophenylamine)-7-methoxy-6(3-(4morpholinyl)quinazoline, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine, gefitinib [Chemical/Ingredient] 
An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal… 
National Institutes of Health

Related topics

Related topics

17 relations

Broader (3)

Antineoplastic AgentsProtein Kinase InhibitorsQuinazolines
Drug AllergyEGFR protein, humanHER1 Antagonists [MoA]Lung Neoplasms

Narrower (2)

IressaZD 1839

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
Background:Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and safety/tolerability of first-line… 
Highly Cited
2010
Highly Cited
2010
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Highly Cited
2009
Highly Cited
2009
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
PURPOSE To compare survival in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated… 
Review
2009
Review
2009
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
Purpose: Tumors from 50% of epidermal growth factor receptor (EGFR) mutant non–small cell lung cancer patients that develop… 
Highly Cited
2008
Highly Cited
2008
Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib
Somatic mutations introduced into the epidermal growth factor receptor (EGFR) gene in non‐small‐cell lung cancer (NSCLC) are… 
Highly Cited
2006
Highly Cited
2006
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been detected in patients with non–small cell lung… 
Highly Cited
2005
Highly Cited
2005
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Non-small cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR… 
Highly Cited
2005
Highly Cited
2005
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
PURPOSE To evaluate epidermal growth factor receptor (EGFR) mutations and copy number as predictors of clinical outcome in… 
Highly Cited
2005
Highly Cited
2005
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar…
PURPOSE Bronchioloalveolar carcinoma (BAC) and adenocarcinomas with BAC features seem to be increasing in incidence, particularly… 
Highly Cited
2004
Highly Cited
2004
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
BACKGROUND Gefitinib, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has activity against… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)